Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis
Background: Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019 (COVID-19) because of its involvement in driving cytokine storm. This systematic review and meta-analysis aimed to assess the safety and efficacy of anti-IL-6 signaling (anti-IL6/IL-6R/JAK) agents on COVID-19 bas...
| Autor principal: | |
|---|---|
| Formato: | Published Article |
| Publicado: |
2020-12-15
|
| Materias: | |
| Acceso en línea: | https://doi.org/10.3389/fphar.2020.615972 https://hdl.handle.net/20.500.12663/2568 |